All In Biotech

Drug Trial Radar · NCT05040490

Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography

Comparison of the Effects of Neostigmine and Sugammadex on Postoperative Residual Curarization and Postoperative Pulmonary Complications Detected by Diaphragm and Lung Ultrasonography: A Study Protocol for Prospective Double-blind Randomized Controlled Trial.

Last checked: Nov 20, 2026Latest source record: Sep 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 414 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

414

Planned (sponsor's estimate)

Start

Aug 31, 2021

Primary completion

Jul 2022

Study completion Sep 2022

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial aims to compare the incidence of postoperative residual curarisation (PORC) and postoperative pulmonary complications (PPCs) in the SUG and NEO group by means of diaphragm ultrasonography and LUS, so as to conclude whether SUG can outperform NEO in preventing occurrence of PORC and PPCs.

Conditions

  • Postoperative Pulmonary Complications

Interventions

  • sugammadex as reversal drugsDrug

    use sugammadex to reverse neuromuscular blockade

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of postoperative pulmonary complicationsTime frame: 30 days after surgery

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.